TradeOrgs
  • šŸ‡®šŸ‡³ India
  • šŸ‡ŗšŸ‡ø US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50ā–² 14.60%TCS₹2,376.20ā–¼ 3.44%HDFCBANK₹846.00ā–² 18.82%ICICIBANK₹1,640.00ā–² 18.75%INFY₹1,098.00ā–¼ 2.89%HINDUNILVR₹2,052.50ā–² 10.75%ITC₹299.10ā–² 14.69%SBIN₹1,165.10ā–² 19.66%BHARTIARTL₹2,161.70ā–² 15.28%KOTAKBANK₹515.80ā–² 16.62%LT₹4,209.10ā–² 14.94%AXISBANK₹1,446.00ā–² 16.99%ASIANPAINT₹2,608.30ā–² 11.91%MARUTI₹14,011.00ā–² 22.10%AAPL$342.56ā–² 0.90%MSFT$484.52ā–¼ 8.90%GOOGL$265.29ā–¼ 22.04%AMZN$246.82ā–¼ 6.02%NVDA$125.53ā–¼ 42.01%META$560.84ā–¼ 19.22%TSLA$345.82ā–¼ 7.46%BRK-B$570.00ā–² 5.59%JPM$310.53ā–¼ 7.38%V$401.87ā–¼ 1.16%
RELIANCE₹1,377.50ā–² 14.60%TCS₹2,376.20ā–¼ 3.44%HDFCBANK₹846.00ā–² 18.82%ICICIBANK₹1,640.00ā–² 18.75%INFY₹1,098.00ā–¼ 2.89%HINDUNILVR₹2,052.50ā–² 10.75%ITC₹299.10ā–² 14.69%SBIN₹1,165.10ā–² 19.66%BHARTIARTL₹2,161.70ā–² 15.28%KOTAKBANK₹515.80ā–² 16.62%LT₹4,209.10ā–² 14.94%AXISBANK₹1,446.00ā–² 16.99%ASIANPAINT₹2,608.30ā–² 11.91%MARUTI₹14,011.00ā–² 22.10%AAPL$342.56ā–² 0.90%MSFT$484.52ā–¼ 8.90%GOOGL$265.29ā–¼ 22.04%AMZN$246.82ā–¼ 6.02%NVDA$125.53ā–¼ 42.01%META$560.84ā–¼ 19.22%TSLA$345.82ā–¼ 7.46%BRK-B$570.00ā–² 5.59%JPM$310.53ā–¼ 7.38%V$401.87ā–¼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy PolicyĀ·Ā© 2026 TradeOrgs

← US stocks

šŸ‡ŗšŸ‡øABOS

Acumen Pharmaceuticals, Inc. - Common Stock

NASDAQ
$0.23
ā–¼ $1.46 (-86.4%)
LiveĀ· just now
delayed feed Ā· not for order timing

Price history Ā· 20-day (cyan) / 50-day (purple) avg

as of 17 Nov 2026
H $3.34L $0.19-90.7%
$3.34$2.71$2.08$1.45$0.82$0.19$0.23
RSI (14)
Intraday Ā· 15-minBuy+35RSI 70UptrendMACD Bullishfor day-trading context — not advice

Technical signal

Strong sell-45
RSI (14)22
oversold 30overbought 70
Trend
Downtrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$0.19
Resistance
$2.52
  • Price is below its 50-day average (medium-term weakness).
  • RSI is 22 — oversold, a level some traders read as a potential entry zone.

Signal backtest Ā· 2026-02-17 → 2026-11-17

Strategy return
-27.6%
Buy & hold
-90.6%
Trades
7
Win rate
14%

$100,000.00 invested would be worth $72,432.73 (-27.6%) Ā· Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Acumen Pharmaceuticals, Inc.Ā· Biotechnology

source: yahoo

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Employees
60
Headquarters
Newton, United States
acumenpharm.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:ā–² Positive1↑ Ā· 0↓ Ā· 7–
  • Alzheimer's families just lost one of their biggest hopes— Neutral
    TheStreet Ā· 10 Nov 2026
  • Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors— Neutral
    Motley Fool Ā· 05 Nov 2026
  • Cantor Fitzgerald Downgrades Acumen Pharmaceuticals to Underweight From Overweight— Neutral
    MT Newswires Ā· 30 Oct 2026
  • Citigroup Downgrades Acumen Pharmaceuticals to Neutral From Buy, Price Target is $1

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

ā–² Positive
MT Newswires Ā· 30 Oct 2026
  • BC-Most Active Stocks— Neutral
    Associated Press Ā· 30 Oct 2026
  • Acumen Pharmaceuticals to Stop Sabirnetug Development in Alzheimer's After Phase 2 Trial Failure— Neutral
    MT Newswires Ā· 30 Oct 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.